Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer

A phase II programme was carried out in both Europe and North America to evaluate the activity of topotecan administered as a 21-day continuous intravenous infusion to patients with recurrent ovarian cancer. The European results are reported here. Patients who had failed first line therapy with a pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Gore, M, Rustin, G, Schüller, J, Lane, S R, Hearn, S, Beckman, R A, Ross, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363856/
https://www.ncbi.nlm.nih.gov/pubmed/11308251
http://dx.doi.org/10.1054/bjoc.2001.1726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363856/
https://www.ncbi.nlm.nih.gov/pubmed/11308251
http://dx.doi.org/10.1054/bjoc.2001.1726

Ejemplares similares